Biden says America’s 'banking system is safe' after regulators back up all SVB deposits March 13, 2023 6:06 am https://www.fiercebiotech.com/biotech/biden-says-americas-banking-system-safe-after-regulators-back-all-svb-deposits

GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy March 13, 2023 4:59 am https://www.fiercebiotech.com/biotech/gsks-100m-adc-bet-doubt-after-fatality-first-trial-mersanas-therapy

UK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK March 13, 2023 3:11 am https://www.fiercebiotech.com/biotech/governments-biotechs-scramble-contain-svb-fallout

SVB capital crunch sends biotechs on bank run March 10, 2023 7:44 am https://www.fiercebiotech.com/biotech/biotech-bank-svbs-capital-crunch-sparks-bank-run-companies-huddle-consider-exposure

After slimming down, Applied Molecular Transport no closer to taking UC drug into phase 3 March 10, 2023 6:34 am https://www.fiercebiotech.com/biotech/after-slimming-down-applied-molecular-transport-no-closer-taking-uc-drug-phase-3

Vyne swings behind BET inhibitors, seeks partner for failed eczema drug March 10, 2023 4:55 am https://www.fiercebiotech.com/biotech/vyne-swings-behind-bet-inhibitors-seeks-partner-failed-eczema-drug

Olema, prioritizing oral SERD, plans 25% head count cut, pulls back from early-stage work March 10, 2023 3:43 am https://www.fiercebiotech.com/biotech/olema-prioritizing-oral-serd-gives-word-25-headcount-cut-pull-back-early-stage-work

Chutes & Ladders—Biogen names Stelios Papadopoulos' successor March 9, 2023 12:35 pm https://www.fiercebiotech.com/biotech/chutes-ladders-biogen-names-papadopoulos-successor

Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic March 9, 2023 6:10 am https://www.fiercebiotech.com/biotech/vertexs-next-shelf-diabetes-cell-therapy-follows-predecessors-footsteps-clinic

FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns March 9, 2023 6:03 am https://www.fiercebiotech.com/biotech/fda-placed-hold-fulcrums-sickle-cell-therapy-over-hematological-malignancy-concerns